

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)



(10) International Publication Number
WO 2022/221696 A1

- (51) **International Patent Classification:**
C07D 473/32 (2006.01) *C12N 15/11* (2006.01)
- (21) **International Application Number:**
PCT/US2022/025075
- (22) **International Filing Date:**
15 April 2022 (15.04.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/176,225 17 April 2021 (17.04.2021) US
- (71) **Applicant: INTELLIA THERAPEUTICS, INC.**
[US/US]; 40 Erie Street, Cambridge, MA 02139 (US).
- (72) **Inventors: MAETANI, Micah;** c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **XIE, Xin Jenny;** c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **FORGET, Anthony;** c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **PRODEUS, Aaron;** c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **YAZINSKI, Stephanie;** c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US). **PARMAR, Rubina Giare;** c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US).
- (74) **Agent: HALSTEAD, David P. et al.;** Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) **Title:** INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF



(57) **Abstract:** The present disclosure relates to inhibitors of DNA protein kinase, and compositions and methods of use thereof. In some embodiments, the inhibitors have the structure of Formula I: or a salt thereof, wherein: x_1 is C-R₃ or N; R₁ is C₁-C₃ alkyl; R₂ is cycloalkyl or heterocyclyl, and cycloalkyl and heterocyclyl are optionally substituted with one or more R₆; R₃ is H or C₁-C₃ alkyl; R₄ is H or C₁-C₃ alkyl; R₅ is C₁-C₃ alkyl; each R₆ is independently selected from hydroxy, halo, alkyl, alkoxy, cycloalkyl, amino, and cyano, or two R₆, taken together with the atom or atoms to which they are bonded, form a spirocyclic or fused ring; and R₇ is H or C₁-C₃ alkyl.

WO 2022/221696 A1